Globus Medical Inc. (GMED)
Here's How Macro Trends and Currency Headwind Restrict GMED's Growth
Globus Medical faces inflation, geopolitical and currency pressures as rising costs and FX losses cloud margin flexibility and international growth.
Globus Medical (GMED) Surges 5.1%: Is This an Indication of Further Gains?
Globus Medical (GMED) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Here's How Innovation Fuels Globus Medical's Growth Momentum
GMED is accelerating product launches, FDA clearances and R&D investment, reinforcing its strategy to expand spine and orthopedic workflows.
Here's How GMED Is Capitalizing on the Musculoskeletal Market Boom
Globus Medical is riding on musculoskeletal market growth with strong Q1 sales gains, double-digit spine growth, and rising trauma demand across key product lines.
Does Globus Medical (GMED) Have the Potential to Rally 38.85% as Wall Street Analysts Expect?
The consensus price target hints at a 38.9% upside potential for Globus Medical (GMED). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
GMED or PEN: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Instruments sector have probably already heard of Globus Medical (GMED) and Penumbra (PEN). But which of these two companies is the best option for those looking for undervalued stocks?
Here's Why Globus Medical (GMED) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's How Financial Strength Remains a Key Advantage for GMED
Globus Medical's debt-free balance sheet, nearly $630M in liquid assets and strong cash flow give it the flexibility to fund growth and support shareholders.
Should You Buy, Hold or Sell GMED Stock Amid Musculoskeletal Boom?
Globus Medical is riding musculoskeletal market growth with spine, trauma and ortho gains, strong cash flow and a debt-free balance sheet.
GMED's Robotics Leasing Shift Could Build Recurring Revenue
Globus Medical is shifting robotics deals to leases and rentals, aiming to expand its installed base and build recurring revenue streams.
GMED Growth Drivers After NuVasive and What Q1 Signals
Globus Medical's Q1 showed margin gains, strong spine and trauma growth, and rising robotics adoption as NuVasive synergies support 2026 targets.
Looking for a Growth Stock? 3 Reasons Why Globus Medical (GMED) is a Solid Choice
Globus Medical (GMED) is well positioned to outperform the market, as it exhibits above-average growth in financials.
